NDA Partners LLC announced today that Dr. Richard C. Siegel, a biologics CMC development expert and former senior executive at Janssen Research and Development, has joined the firm as a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants who design and implement critical solutions to help clients successfully develop new medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.
Rochelle, Virginia (PRWEB) October 21, 2015
Dr. Carl Peck, MD, Chairman of NDA Partners LLC announced today that Dr. Richard C. Siegel, has joined the firm as an Premier Expert consultant. NDA Partners Premier Experts are top tier consultants whose expertise and professional stature enable them to bring extraordinary value to the company's clients. Premier Experts collaborate to design and implement critical solutions to help clients successfully develop their medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.
Dr. Siegel is an experienced biologics CMC development expert providing technical and strategic guidance on both early and late stage development activities, and a technical expert in process development and manufacture of monoclonal antibodies, therapeutic proteins and conjugates, peptides, cellular products and oligonucleotides. He was formally the Vice President and Global Head of Portfolio Management, and Vice President and Global Head of Large Molecule Portfolio Management and Technical Integration at Janssen Research and Development; Vice President of API Technical Operations at the Global Pharmaceutical Supply Group (a J&J company); and Vice President of New Technology and Business Management with Global Biologics Supply Chain (a J&J company). Dr. Siegel has also held several senior executive positions at Centocor Research and Development during which time he was responsible for the overall management of the Pharmaceutical Development department. Over his career, Dr. Siegel led process development for six licensed monoclonal antibody products.
According to Dr. Peck, “Dr. Siegel brings an exceptional level of expertise and experience to our clients in the area of biologics CMC process development and manufacturing, including monoclonal antibodies, therapeutic proteins and conjugates, peptides, cellular products and oligonucleotides. Dr. Siegel is a welcome addition to NDA Partners and a valuable new asset on our executive consulting team serving leading edge biotechnology clients.”
Dr. Siegel received a PhD in Biochemistry from Tufts University and was a Postdoctoral Scholar in the Department of Chemistry and the Department of Microbiology and Immunology at the University of Los Angeles, California. He was formally on the Board of Directors for Centyrex, a Johnson & Johnson Development Corp. venture.
About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 40 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/10/prweb13031442.htm